Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S32.003)
Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available
10.1212/wnl.0000000000204564